BindingDB Entry 2846: Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.

Name: BindingDB Entry 2846: Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.
Creator: BindingDB
Keywords: Tyrosine Kinase EphB4, AstraZeneca, Affinity, 3. Good health

Research datakeyboard_double_arrow_right Dataset 01 Jan 2008 English Publisher:BindingDB

Authors: BindingDB;

doi: 10.7270/q2c827mh

BindingDB Entry 2846: Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.

- Summary
- Subjects
- Related research
  (10)
- Metrics

tips_and_updates
Recommended

Abstract

Small molecule binding data for protein Tyrosine Kinase EphB4, Uniprot P54760 and Q541P7

Keywords

Tyrosine Kinase EphB4, AstraZeneca, Affinity

10 Research products, page 1 of 1

BindingDB Entry 50033157: Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.
2011IsAmongTopNSimilarDocuments
BindingDB Entry 50047288: Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.
2017IsAmongTopNSimilarDocuments
Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines
2008IsDerivedFrom
BindingDB Entry 50022332: Entry into a new class of protein kinase inhibitors by pseudo ring design.
2009IsAmongTopNSimilarDocuments
BindingDB Entry 50038281: Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model.
2012IsAmongTopNSimilarDocuments
BindingDB Entry 50030256: Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines.
2010IsAmongTopNSimilarDocuments
BindingDB Entry 50046878: ¿(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system.
2017IsAmongTopNSimilarDocuments
BindingDB Entry 50046213: Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation.
2016IsAmongTopNSimilarDocuments
BindingDB Entry 50042640: Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography.
2013IsAmongTopNSimilarDocuments
BindingDB Entry 3977: Dose-response biochemical assay for antagonists of the interaction between the Eph receptor B4 (EphB4) and its ligand ephrin-B2 via TNYL-RAW peptide
2011IsAmongTopNSimilarDocuments

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average